MVI Logo

Senior Management

Richard R. Lesniewski, PhD is Co-founder, President and Chief Executive Officer of MVI

Dr. Lesniewski has 30 years of operational and leadership experience in pharmaceuticals and diagnostics, including careers at Abbott Laboratories (North Chicago) and GlaxoSmithKline (Philadelphia). As Vice President of Oncology Biopharmaceuticals for GSK, Rick led a new Biopharmaceutical Drug Performance Unit (DPU) within GSK’s Global Oncology Business Unit. He established GSK’s relationship with Seattle Genetics for antibody drug conjugates, and started their PD-1 antagonist program via strategic alliance with Amplimmune (Rockville, MD).

Prior to joining GSK, Rick had a 25-year career with Abbott Laboratories (1983-2009) where he held multiple leadership positions within the Global Pharmaceuticals Cancer Research Organization, heading discovery and optimization of biopharmaceutical agents, and later founding new research programs in tumor genomics, cancer biomarkers, and therapeutic antibody discovery. As Director of Cancer Research, Dr. Lesniewski also led the Department of Biomarker Discovery Research, and integrated personalized medicine strategies across the Abbott Oncology drug portfolio. Prior to these roles, Dr. Lesniewski served in a technology assessment and licensing role within Abbott’s Global Pharmaceutical Division. There he helped establish the Division’s first oncology therapeutic area, driving successful partnering initiatives with Northwestern University, Idun Pharmaceuticals (ABT-263, Navitoclax) and Yale University. During his first 12 years with Abbott, Rick led teams in discovery of novel viral diagnostic tests, and helped Abbott Diagnostics Division develop and launch their franchise leadership in hepatitis C virus blood screening assays. Dr. Lesniewski’s experience covers novel biopharmaceutical drug and companion diagnostics discovery research, translational drug development, creating and managing productive strategic alliances, and leading drug development partnerships from early discovery to the clinic.

Dr. Lesniewski currently sits on the Board of Directors of DNASTAR, Invenra, and Scarab Genomics, and on the Scientific Advisory Board of Alethia Biotherapeutics.


Douglas McNeel, MD, PhD is the Chief Scientific Founder of MVI and Head of MVI's Scientific Advisory Board.

Dr. McNeel is Professor of Medicine at the University of Wisconsin, Madison. He is a genitourinary medical oncologist with a laboratory and clinical research program that has focused on prostate cancer immunology for over a decade.

The long-term goal of Dr. McNeel’s research efforts is to develop effective anti-tumor vaccines as treatments for prostate cancer. His current research efforts seek to identify immunologically recognized proteins of the prostate, characterize these as tumor target antigens, and evaluate anti-tumor genetic vaccines targeting these antigens in appropriate pre-clinical models. Dr. McNeel is specifically evaluating plasmid DNA vaccines encoding these antigens, and is actively translating these findings in early phase human clinical trials.

Dr. McNeel is the primary author of multiple issued patents covering the prostatic acid phosphatase and androgen receptor plasmid DNA vaccines, as well as for pending patents on potential biomarkers of patient response to the PAP vaccine. His work provides the underpinning scientific and clinical innovation for MVI.


Todd Argall, CPA, is Vice President –Finance and Secretary / Treasurer of MVI

Mr. Argall is responsible for all finance-related matters at MVI, including budgeting, cash management, accounting, reporting, tax returns, etc. Prior to joining MVI, Mr.Argall spent seven years in public accounting and sixteen years in the private equity industry before becoming Vice President– Finance of a local life science company. Mr. Argall’s private equity experience included serving as Chief Financial Officer of Wind Point Partners, a Midwest-focused private equity firm, and Partner and Executive Director in charge of investment accounting and financial operations for Brinson Partners, Inc.'s private equity group (now Adams Street Partners) in Chicago. Mr. Argall is a Certified Public Accountant with a BS in Accounting from the University of Wisconsin - Platteville and earned the "Elijah Watt Sells with High Distinction" award for his performance on the November 1982 CPA exam.